Headache News and Research

Latest Headache News and Research

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Exchanges: HHS official offers insights on state deadline, insurer roles

During a news briefing in Washington, D.C., Steve Larsen, deputy administrator and director of the Center for Consumer Information and Insurance Oversight at the CMS, discussed certain issues related to the establishment of state health exchanges.

22 Jul 2011

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

Summer heat prompts SCAN to issue dehydration warning for seniors

Seniors are six times more likely to be admitted to the hospital due to dehydration than adults ages 45-64. Prompted by the summer heat, SCAN Health Plan Arizona is issuing a warning to seniors to stay hydrated and know the signs of dehydration.

21 Jul 2011

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.

21 Jul 2011

Software uses Twitter to track dengue outbreaks in Brazil

The New Scientist reports on a software program that is being used "to identify a high correlation between the time and place where people tweet they have dengue and the official statistics for where the disease appears each season."

20 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Tips for preventing heat-related illness

With "feels-like" temperatures approaching or exceeding 100 degrees forecast for parts of Pennsylvania this week, the Department of Health is reminding all Pennsylvanians of important steps they can take to protect their health.

20 Jul 2011

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

The Influenza Specialist Group (ISG) is today warning that high rates of influenza outbreaks have been confirmed in QLD, SA and NSW, but there is still time for most Australians, especially those in at-risk groups, to protect themselves and those around them.

18 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

FDA warns consumers not to drink raw milk from Tucker Adkins Dairy

The FDA is working with officials in North Carolina and South Carolina to investigate an outbreak of campylobacteriosis in three people who consumed raw milk from Tucker Adkins Dairy in York, S.C. The three confirmed cases and another five probable cases are from three different households and each case reports that prior to becoming ill they consumed raw milk that was obtained from Tucker Adkins Dairy on June 14, 2011.

18 Jul 2011

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

Tips for avoiding heat stroke

As a major heat wave sweeps over the country, the University of Alabama at Birmingham Hospital has already treated one patient for heat stroke and is gearing up for more.

13 Jul 2011

Headache News and Research

Latest Headache News and Research

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Exchanges: HHS official offers insights on state deadline, insurer roles

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Public disclosure of Bachmann's migraine condition raises much-needed awareness

Summer heat prompts SCAN to issue dehydration warning for seniors

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Software uses Twitter to track dengue outbreaks in Brazil

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Tips for preventing heat-related illness

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

FDA warns consumers not to drink raw milk from Tucker Adkins Dairy

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Tips for avoiding heat stroke

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in